

A Phase I/II Study of Intraperitoneal Paclitaxel in Patients With Metastatic Appendiceal Adenocarcinoma

NCT06207305

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	M.D. Anderson Cancer Center
Enrollment	39 participants

Key Eligibility Criteria

Inclusion (18)

- Age 18 years and above. There will be no upper age restriction
- ECOG performance status d 2
- Participants must have histologically confirmed diagnosis of unresectable locally metastatic appendiceal adenocarcinoma
- Metastatic disease in the peritoneal cavity and not a candidate for cytoreductive surgery
- Participants must have adequate organ and marrow function as defined below:
... and 13 more (see full listing online)

Exclusion (10)

- Active infection such as pneumonia or wound infections that would preclude protocol therapy
- Participants with unstable angina or New York Heart Association (NYHA) Grade II or greater congestive heart failure
- Participants deemed unable to comply with study and/or follow-up procedures (i.e., cognitive impairment)
- Participants with a known hypersensitivity to protocol systemic chemotherapy that was life-threatening, required hospitalization or prolongation of existing hospitalization, or resulted in persistent or significant disability or incapacity
- Previous surgery that would preclude safe diagnostic laparoscopy with port placement
... and 5 more (see full listing online)

Locations (1 total)

MD Anderson Cancer Center, Houston, Texas, United States